Cardio Diagnostics Holdings, Inc. (CDIO), a company specialising in AI-driven cardiovascular medicine, announced a strategic partnership with Navierre, a forward-thinking digital health technology platform. This partnership aims to increase accessibility to Cardio Diagnostics' state-of-the-art, AI-enhanced precision cardiovascular diagnostic tests.
Capitalising on the rising trend of telehealth, Cardio Diagnostics and Navierre aim to transform patient cardiovascular care. They intend to do this by facilitating earlier detection, ensuring accessible specialist care and enabling personalised prevention.
Cardio Diagnostics offers a suite of AI-driven solutions, notable among them being the Epi+Gen CHD and PrecisionCHD tests. These tools utilise avant-garde epigenetic and genetic science to deliver customised insights into a patient's risk for coronary heart disease.
In partnering with Navierre, these groundbreaking diagnostic instruments will be made accessible to a wider demographic, thus bridging the gap to specialist cardiovascular treatment.
Effective from April 1, 2024, Cardio Diagnostics' precision heart health tests, featuring leading AI-empowered epigenetic-genetic cardiovascular risk, detection, and management tests, will be offered to thousands of patients and doctors through Navierre's platform.
Clinicians partnered with Navierre across the U.S will have the facility to effortlessly order these tests for their patients. Simultaneously, consumers can conveniently set up a profile on the platform, complete a health questionnaire and request the clinical test.
